Organic compounds -- part of the class 532-570 series – Organic compounds – Cyclopentanohydrophenanthrene ring system containing
Reexamination Certificate
1998-07-08
2002-05-21
Wilson, Michael C. (Department: 1633)
Organic compounds -- part of the class 532-570 series
Organic compounds
Cyclopentanohydrophenanthrene ring system containing
C536S005000
Reexamination Certificate
active
06392069
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention pertains to the field of delivering therapeutic and other agents to cells. Genes, polypeptides, and other molecules are among the agents that can be delivered using the compounds and methods of the invention. The cells can be present individually or as a biological tissue or organ.
Delivery of a compound into a cell is a first critical step for many diagnostic and therapeutic processes. Gene therapy, for example, is a highly promising tool for therapeutic and other uses that requires delivery of a nucleic acid to a cell. For example, distinct approaches have been developed to treat neoplasms based on gene transfer methods. Methods have been developed to correct specific lesions at defined genetic loci which give rise to neoplastic transformation and progression (Spandidos et al.,
Anticancer Res
. 10:1543-1554 (1990); Banerjee et al.,
Cancer Res
. 52:6297-6304 (1992)). Overexpression of dominant oncogenes may be addressed using techniques to inhibit the transforming gene or gene product. Loss of tumor suppressor gene function may be approached using methods to reconstitute wild-type tumor suppressor gene function (Goodrich et al.,
Cancer Res
. 52:1968-1973 (1992)). Besides these methods to achieve mutation compensation, genetic techniques have been developed to specifically and selectively eradicate tumor cells. These approaches of molecular chemotherapy rely on specific expression of toxin genes in neoplastic cells (Abe et al.,
Proc Soc Exp Biol Med
. 203:354-359 (1993)). Finally, gene transfer methods have been used to achieve antitumor immunization. These methods of genetic immunopotentiation use techniques of genetic immunoregulation to enhance immune recognition of tumors. Consequently, a variety of distinct approaches have been developed to accomplish gene therapy of cancer.
A high incidence of mutations has been observed in tumor suppressor genes, such as p53 and RB, in the case of carcinoma of the bladder (Fujimoto et al.,
Cancer Res
. 52:1393-1398 (1992); Cairns et al.,
Oncogene
6:2305-2309 (1991)). For such genetic lesions of tumor suppressor genes, reversion of the neoplastic phenotype can be demonstrated with replacement of the corresponding wild-type tumor suppressor gene (Spandidos, Id.; Banerjee, Id.).
Carcinoma of the bladder represents a significant source of morbidity and mortality. Bladder cancer ranks 10th in males and 12th in females in cancer related mortality (Cancer Facts and Figures,
Amer. Can. Soc
. 5:11 (1995)). Therapies available for the treatment of bladder cancer include adjuvant chemotherapy or immunotherapy, transurethral resection of superficial disease, radical cystectomy or radiotherapy which is often combined with systemic chemotherapy. Despite these therapeutic options, overall survival has not changed appreciably. (Id.) Thus, new therapeutic modalities must be developed for the treatment of bladder cancer.
Gene therapy strategies have been developed as an alternative therapeutic approach (See for example, Brewster et al.,
Eur Urol
25:177-182 (1994); Takahashi et al.,
Proc Natl Acad Sci USA
88: 5257-5261 (1991); Rosenberg, S A,
J. Clin Oncol
. 10:180-199 (1992)). Successful treatment of cancer and other conditions in a human or other animal can depend upon an adequate amount of a therapeutic agent entering the cells, and upon a large enough proportion of target cells taking up the therapeutic agent.
Many other therapeutics and other modulating agents are polypeptides or, for example, small molecules. Again, the amount of the agent that reaches a target cell population can have a great impact on the efficacy of treatment. Therefore, a need exists for compounds and methods that can enhance the amount of an agent that is delivered to a cell or a population of cells.
The present invention fulfils this and other needs.
SUMMARY OF THE INVENTION
The invention provides compounds that can enhance delivery of an agent to cells. The delivery enhancing compounds of the invention typically have a Formula I:
wherein:
m and n are the same or different and each is an integer from 2-8; R is a cationic group or
X
1
is selected from the group consisting of:
and X
2
and X
3
are each independently selected from the group consisting of a saccharide group,
wherein at least one of X
2
and X
3
is a saccharide group when R is
Some examples of preferred delivery enhancing compounds of the invention are those that have a Formula III, IV, or V as shown in FIG.
21
.
In some embodiments, the delivery enhancing compounds have a Formula II:
wherein X
1
and X
2
are selected from the group consisting of
and X
3
is a saccharide group.
Also provided by the invention are methods of delivering an agent to cells by administering the agent to the cells in a formulation that includes a delivery enhancing compound of Formula I.
In additional embodiments, the invention provides compositions for delivering an agent to cells. The compositions include the agent to be delivered and a delivery enhancing compound of Formula I.
A further aspect of the invention is a method of treating cancer, including bladder cancer, by administering to a cell a therapeutically effective amount of a therapeutic agent that is formulated in a buffer comprising a compound of Formula I.
REFERENCES:
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5108921 (1992-04-01), Low et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5279833 (1994-01-01), Rose
patent: 5283185 (1994-02-01), Epand et al.
patent: 5334761 (1994-08-01), Gebeyehu et al.
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5542935 (1996-08-01), Unger et al.
patent: 5552309 (1996-09-01), March
patent: 5554386 (1996-09-01), Groman et al.
patent: 5578475 (1996-11-01), Jessee
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5601818 (1997-02-01), Freeman et al.
patent: 5631236 (1997-05-01), Woo et al.
patent: 5804566 (1998-09-01), Carson et al.
patent: 6210939 (2001-04-01), Gregory et al.
patent: WO 92/06180 (1992-04-01), None
patent: WO 93/14188 (1993-07-01), None
patent: WO 93/19768 (1993-10-01), None
patent: WO 93/20221 (1993-10-01), None
patent: WO 94/06922 (1994-03-01), None
patent: WO 94/06923 (1994-03-01), None
patent: WO 97/05209 (1997-02-01), None
patent: WO 97/27599 (1997-07-01), None
Verma et al. Nature, vol. 389, pp. 239-242, Sep. 18, 1997.*
Ross et al. Human Gene Therapy, vol. 7, pp. 1781-1790, Sep. 1996.*
Marshall Science, vol. 269, pp. 1050-1055, 1995.*
Shawaphun et al., Chemical evidence for transbilayer movement of molecular umbrellas, 1999, J. Am. Chem. Soc., vol. 121, pp. 5860-5864.*
Aungst, B. and Rogers, N., “Comparison of the effects of various transmucosal absorption promoters on buccal insulin delivery,”Inter. J. of Pharmaceutics,53:227-235 (1989).
Janout, V. et al., “Evidence for Highly Cooperative Binding between Molecular Umbrella—Spermine Conjugates and DNA,”Bioconjugate Chem.,8:891-895 (1997).
Janout, V. et al., “Molecular Umbrellas,”J. Am. Chem. Soc.118:1573-1574 (1996).
Helenius et al. (1979) “Properties of Detergents” In:Methods in Enzymology,vol. 56, 734-749.
Abe, A. et al., “Transduction of a Drug-Sensitive Toxic Gene into Human Leukemia Cell Lines with a Novel Retroviral Vector,”P.S.E.B.M.203:354-359 (1993).
Arteaga, C.L. et al., “Tissue-targeted Antisense c-fos Retroviral Vector Inhibits Established Breast Cancer Xenografts in Nude Mice,”Cancer Research56:1098-1103 (1996).
Banerjee, A. et al., “Changes in Growth and Tumorigenicity following Reconstitution of Retinoblastoma Gene Function in Various Human Cancer Cell Types of Microcell Transfer of Chromosome 13,”Cancer Research52:6297-6304 (1992).
Bass, C. et al., “Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo,”Cancer Gene Ther.2(2):97-104 (1995).
Blixt, Y. et al., “Enhancement of intracellular uncoating of adenovirus in HeLa cells in the presence of benzyl alcohol as a membrane fluidizer,”Arch. Virol.129
Engler Heidrun
Nagabhushan Tattanahalli L.
Youngster Stephen Kenneth
Canji Inc.
Townsend and Townsend / and Crew LLP
Wilson Michael C.
LandOfFree
Compositions for enhancing delivery of nucleic acids to cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for enhancing delivery of nucleic acids to cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for enhancing delivery of nucleic acids to cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2837018